The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.
There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback